Marshall Wace
SEEL

Marshall Wace’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Marshall Wace’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-159
Closed -$3.04M – 3197
2021
Q1 		$3.04M Buy
159
+156
+5,200% +$1.82M 0.01% 1107
2020
Q4 		$18K Buy
+3
New +$11.8K ﹤0.01% 1826

Other funds holding SEEL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Marshall Wace's SEEL Position: Q2 2021 in Review

Marshall Wace sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q2 2021, closing a stake of 159 shares — an estimated $3.04M sold.

Marshall Wace first reported a position in SEEL in Q4 2020 and held it in 2 quarters. The position peaked at $3.04M in Q1 2021. 92 funds tracked by Wall St. Rank hold SEEL as of Q2 2021.

  • Marshall Wace reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace sold 159 Seelos Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $3.04M.
  • Marshall Wace first reported a position in Seelos Therapeutics, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • Marshall Wace's Seelos Therapeutics, Inc. Common Stock position peaked at $3.04M in Q1 2021.
  • 92 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Marshall Wace's 13F filing for Q2 2021, filed 13 Aug 2021.